The lack of autophagy and reduced HMGB1 expression have been associated with extremely poor prognosis in breast cancer specimens [87] and potentially with adverse effects on immune surveillance by anticancer drugs, and thereby with the promotion of tumor progression [88]. Here, HMGB1 is linked to breast cancer.